Literature DB >> 19464416

Comparison of the intracoronary continuous infusion method using a microcatheter and the intravenous continuous adenosine infusion method for inducing maximal hyperemia for fractional flow reserve measurement.

Myeong-Ho Yoon1, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Sun Park, Mingri Zheng, Hong-Seok Lim, Byoung-Joo Choi, So-Yeon Choi, Un-Jung Choi, Joung-Won Hwang, Soo-Jin Kang, Gyo-Seung Hwang, Joon-Han Shin.   

Abstract

BACKGROUND: Inducing stable maximal coronary hyperemia is essential for measurement of fractional flow reserve (FFR). We evaluated the efficacy of the intracoronary (IC) continuous adenosine infusion method via a microcatheter for inducing maximal coronary hyperemia.
METHODS: In 43 patients with 44 intermediate coronary lesions, FFR was measured consecutively by IC bolus adenosine injection (48-80 microg in left coronary artery, 36-60 microg in the right coronary artery) and a standard intravenous (IV) adenosine infusion (140 microg x min(-1) x kg(-1)). After completion of the IV infusion method, the tip of an IC microcatheter (Progreat Microcatheter System, Terumo, Japan) was positioned at the coronary ostium, and FFR was measured with increasing IC continuous adenosine infusion rates from 60 to 360 microg/min via the microcatheter.
RESULTS: Fractional flow reserve decreased with increasing IC adenosine infusion rates, and no further decrease was observed after 300 microg/min. All patients were well tolerated during the procedures. Fractional flow reserves measured by IC adenosine infusion with 180, 240, 300, and 360 microg/min were significantly lower than those by IV infusion (P < .05). Intracoronary infusion at 180, 240, 300, and 360 microg/min was able to shorten the times to induction of optimal and steady-stable hyperemia compared to IV infusion (P < .05). Functional significances were changed in 5 lesions by IC infusion at 240 to 360 microg/min but not by IV infusion.
CONCLUSIONS: The results of this study suggest that an IC adenosine continuous infusion method via a microcatheter is safe and effective in inducing steady-state hyperemia and more potent and quicker in inducing optimal hyperemia than the standard IV infusion method.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464416     DOI: 10.1016/j.ahj.2009.03.012

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

Review 1.  Fractional flow reserve as a surrogate for inducible myocardial ischaemia.

Authors:  Tim P van de Hoef; Martijn Meuwissen; Javier Escaned; Justin E Davies; Maria Siebes; Jos A E Spaan; Jan J Piek
Journal:  Nat Rev Cardiol       Date:  2013-06-11       Impact factor: 32.419

2.  Clinical Outcomes in Patients with Deferred Coronary Lesions according to Disease Severity Assessed by Fractional Flow Reserve.

Authors:  Ki Bum Won; Chang Wook Nam; Yun Kyeong Cho; Hyuck Jun Yoon; Hyoung Seob Park; Hyungseop Kim; Seongwook Han; Seung Ho Hur; Yoon Nyun Kim; Sang Hyun Park; Jung Kyu Han; Bon Kwon Koo; Hyo Soo Kim; Joon Hyung Doh; Sung Yun Lee; Hyoung Mo Yang; Hong Seok Lim; Myeong Ho Yoon; Seung Jea Tahk; Kwon Bae Kim
Journal:  J Korean Med Sci       Date:  2016-12       Impact factor: 2.153

3.  Intracoronary versus intravenous adenosine-induced maximal coronary hyperemia for fractional flow reserve measurements.

Authors:  Ahmed Khashaba; Ayman Mortada; Azza Omran
Journal:  Clin Med Insights Cardiol       Date:  2014-02-12

Review 4.  Physiologic Assessment of Coronary Artery Disease: Focus on Fractional Flow Reserve.

Authors:  Doyeon Hwang; Joo Myung Lee; Bon-Kwon Koo
Journal:  Korean J Radiol       Date:  2016-04-14       Impact factor: 3.500

5.  Intravascular ultrasound characteristics in patients with intermediate coronary lesions and borderline fractional flow reserve measurements.

Authors:  Hyoung-Mo Yang; Hong-Seok Lim; Kyoung-Woo Seo; Byoung-Joo Choi; So-Yeon Choi; Myeong-Ho Yoon; Gyo-Seung Hwang; Seung-Jea Tahk
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.